Fusion Pharmaceuticals to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
Fusion Pharmaceuticals, a clinical-stage oncology company listed on Nasdaq under the ticker FUSN, announced its participation at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022, at 3:30 p.m. ET. CEO John Valliant, Ph.D., will present at the event in Toronto, Ontario. A live webcast can be accessed via the company's website's 'Investors & Media' section, with a replay available for 60 days. Fusion specializes in developing next-generation radiopharmaceuticals, including their lead program targeting insulin-like growth factor 1 receptor, currently in Phase 1 trials.
- None.
- None.
Insights
Analyzing...
HAMILTON, ON and BOSTON, April 26, 2022 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that the Company will present at the 2022 Bloom Burton & Co. Healthcare Investor Conference in Toronto, Ontario on Monday, May 2, 2022 at 3:30 p.m. ET. Presenting on behalf of Fusion will be Chief Executive Officer John Valliant, Ph.D.
A live webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for 60 days following the presentation.
About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Fusion connects alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434 targeting insulin-like growth factor 1 receptor, is currently in a Phase 1 clinical trial. The pipeline includes FPI-1966, targeting the fibroblast growth factor receptor 3 (FGFR3), advancing to a Phase 1 study following the recent investigational new drug (IND) clearance; and FPI-2059, a small molecule targeting neurotensin receptor 1 (NTSR1). In addition to a robust proprietary pipeline, Fusion has a collaboration with AstraZeneca to jointly develop novel targeted alpha therapies (TATs) and combination programs between Fusion's TATs and AstraZeneca's DNA Damage Repair Inhibitors (DDRis) and immuno-oncology agents. Fusion has also entered into a collaboration with Merck to evaluate FPI-1434 in combination with Merck's KEYTRUDA® (pembrolizumab) in patients with solid tumors expressing IGF-1R. Fusion and Hamilton, Ontario-based McMaster University are building a current Good Manufacturing Practice (GMP) compliant radiopharmaceutical manufacturing facility designed to support manufacturing of the Company's growing pipeline of TATs.
For further information: Amanda Cray, Senior Director of Investor Relations & Corporate Communications, 617-967-0207, cray@fusionpharma.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-2022-bloom-burton--co-healthcare-investor-conference-301533624.html
SOURCE Fusion Pharmaceuticals Inc.
FAQ
When is Fusion Pharmaceuticals presenting at the 2022 Bloom Burton Conference?
Who will represent Fusion Pharmaceuticals at the conference?
Where will the 2022 Bloom Burton Conference take place?
How can I watch the Fusion Pharmaceuticals presentation?
What is the focus of Fusion Pharmaceuticals?
